Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern
Liane Dupont, Luke B. Snell, Carl Graham, et al.
Nature Microbiology (2021) Vol. 6, Iss. 11, pp. 1433-1442
Open Access | Times Cited: 106

Showing 26-50 of 106 citing articles:

Comparative analysis of SARS-CoV-2 neutralization titers reveals consistency between human and animal model serum and across assays
Barbara Mühlemann, Samuel Wilks, Lauren Baracco, et al.
Science Translational Medicine (2024) Vol. 16, Iss. 747
Closed Access | Times Cited: 5
Identification of TCR repertoires in functionally competent cytotoxic T cells cross-reactive to SARS-CoV-2
Kanako Shimizu, Tomonori Iyoda, An Sanpei, et al.
Communications Biology (2021) Vol. 4, Iss. 1
Open Access | Times Cited: 27
Predicting Vaccine Effectiveness for Hospitalization and Symptomatic Disease for Novel SARS-CoV-2 Variants Using Neutralizing Antibody Titers
Billy J. Gardner, A. Marm Kilpatrick
Viruses (2024) Vol. 16, Iss. 3, pp. 479-479
Open Access | Times Cited: 4
Hamiltonian optimal control of quarantine against epidemic spreading on complex networks
Yufei Fan, Xueyu Meng, Jun Liu, et al.
Chaos Solitons & Fractals (2025) Vol. 194, pp. 116240-116240
Closed Access
Geographical Differences in SARS-CoV-2 Antibody Response Dynamics and Neutralisation Profiles to Mild COVID-19: Lessons from a UK–Uganda Comparison
Laban Kato, Jackson Sembera, Gerald Kevin Oluka, et al.
Vaccines (2025) Vol. 13, Iss. 4, pp. 336-336
Open Access
Role of Dengue in SARS-CoV-2 Evolution in Dengue Endemic Regions
Abinash Mallick, Subhajit Biswas
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
Luteolin Potentially Treating Prostate Cancer and COVID-19 Analyzed by the Bioinformatics Approach: Clinical Findings and Drug Targets
Ye Yu, Ziyan Huang, Manying Chen, et al.
Frontiers in Endocrinology (2022) Vol. 12
Open Access | Times Cited: 17
High-Throughput Neutralization and Serology Assays Reveal Correlated but Highly Variable Humoral Immune Responses in a Large Population of Individuals Infected with SARS-CoV-2 in the US between March and August 2020
Shuting Zhang, Peijun Ma, Marek Orzechowski, et al.
mBio (2023) Vol. 14, Iss. 2
Open Access | Times Cited: 10
Assessment of the Biological Impact of SARS-CoV-2 Genetic Variation Using an Authentic Virus Neutralisation Assay with Convalescent Plasma, Vaccinee Sera, and Standard Reagents
Naomi S. Coombes, Kevin R. Bewley, Yann Le Duff, et al.
Viruses (2023) Vol. 15, Iss. 3, pp. 633-633
Open Access | Times Cited: 10
Validation and Suitability Assessment of Multiplex Mesoscale Discovery Immunogenicity Assay for Establishing Serological Signatures Using Vaccinated, Non-vaccinated and Breakthrough SARS-COV-2 Infected Cases
Sushant Shengule, Shweta Alai, Sachin Bhandare, et al.
(2024)
Open Access | Times Cited: 3
Immune Response to COVID-19 Vaccination in Frontline Healthcare Workers
Birutė Strukčinskienė, Zydre Valotkiene, Jonas Jurgaitis, et al.
Vaccines (2024) Vol. 12, Iss. 2, pp. 199-199
Open Access | Times Cited: 3
Cohort profile:Stop the Spread Ottawa (SSO)—a community-based prospective cohort study on antibody responses, antibody neutralisation efficiency and cellular immunity to SARS-CoV-2 infection and vaccination
Erin Collins, Yannick Galipeau, Corey Arnold, et al.
BMJ Open (2022) Vol. 12, Iss. 9, pp. e062187-e062187
Open Access | Times Cited: 16
ChAdOx1 nCoV-19 vaccine elicits monoclonal antibodies with cross-neutralizing activity against SARS-CoV-2 viral variants
Jeffrey Seow, Carl Graham, Sadie R. Hallett, et al.
Cell Reports (2022) Vol. 39, Iss. 5, pp. 110757-110757
Open Access | Times Cited: 15
Distinct antigenic properties of the SARS-CoV-2 Omicron lineages BA.4 and BA.5
Brian J. Willett, Ashwini Kurshan, Nazia Thakur, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 15
Immunogenic properties of SARS-CoV-2 inactivated by ultraviolet light
A. V. Gracheva, E. R. Korchevaya, Yu. I. Ammour, et al.
Archives of Virology (2022) Vol. 167, Iss. 11, pp. 2181-2191
Open Access | Times Cited: 14
Immunodominant antibody responses directed to SARS-CoV-2 hotspot mutation sites and risk of immune escape
Jamille Ramos Oliveira, César Remuzgo, Rafael Rahal Guaragna Machado, et al.
Frontiers in Immunology (2023) Vol. 13
Open Access | Times Cited: 8
Antigenic cartography using variant-specific hamster sera reveals substantial antigenic variation among Omicron subvariants
Barbara Mühlemann, Jakob Trimpert, Felix Walper, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 8
Broad and potent neutralizing antibodies are elicited in vaccinated individuals following Delta/BA.1 breakthrough infection
Jeffrey Seow, Zayed A. Shalim, Carl Graham, et al.
mBio (2023) Vol. 14, Iss. 5
Open Access | Times Cited: 8
Comparative Study of the Mutations Observed in the SARS-CoV-2 RBD Variants of Concern and Their Impact on the Interaction with the ACE2 Protein
Mariem Ghoula, Audrey Deyawe Kongmeneck, Rita Eid, et al.
The Journal of Physical Chemistry B (2023) Vol. 127, Iss. 40, pp. 8586-8602
Open Access | Times Cited: 8
Neutralising antibody activity against SARS-CoV-2 variants, including Omicron, in an elderly cohort vaccinated with BNT162b2
Joseph Newman, Nazia Thakur, Thomas P. Peacock, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 19
Shared N417-Dependent Epitope on the SARS-CoV-2 Omicron, Beta, and Delta Plus Variants
Thandeka Moyo-Gwete, Mashudu Madzivhandila, Nonhlanhla N. Mkhize, et al.
Journal of Virology (2022) Vol. 96, Iss. 15
Open Access | Times Cited: 13
The effect of Omicron breakthrough infection and extended BNT162b2 booster dosing on neutralization breadth against SARS-CoV-2 variants of concern
Carl Graham, Thomas Lechmere, Aisha Rehman, et al.
PLoS Pathogens (2022) Vol. 18, Iss. 10, pp. e1010882-e1010882
Open Access | Times Cited: 13
Pre-Omicron Vaccine Breakthrough Infection Induces Superior Cross-Neutralization against SARS-CoV-2 Omicron BA.1 Compared to Infection Alone
Eveline Santos da Silva, Michel Kohnen, Georges Gilson, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 14, pp. 7675-7675
Open Access | Times Cited: 12
Enhanced immune responses following heterologous vaccination with self-amplifying RNA and mRNA COVID-19 vaccines
Tamara Elliott, Hannah M. Cheeseman, Abbey Evans, et al.
PLoS Pathogens (2022) Vol. 18, Iss. 10, pp. e1010885-e1010885
Open Access | Times Cited: 12
Cross-protective HCoV immunity reduces symptom development during SARS-CoV-2 infection
Irène A. Abela, Magdalena Schwarzmüller, Agnė Ulytė, et al.
mBio (2024) Vol. 15, Iss. 2
Open Access | Times Cited: 2

Scroll to top